(Q46231324)

20 December 2017

title

Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes (English)

1 reference

20 December 2017

main subject

phase II clinical trial

0 references

author

Sylvie Chevret

series ordinal

3

1 reference

20 December 2017

Matthieu Resche-Rigon

object named as

Matthieu Resche-Rigon

series ordinal

1

0 references

author name string

Sarah Zohar

series ordinal

2

1 reference

20 December 2017

publication date

1 January 2008

1 reference

20 December 2017

published in

Clinical Trials

1 reference

20 December 2017

volume

5

1 reference

20 December 2017

issue

6

1 reference

20 December 2017

page(s)

595-606

1 reference

20 December 2017

Clinical trial designs for cytostatic agents: are new approaches needed?

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Design and analysis of phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Bayesian methods for phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Bayesian decision procedures for dose determining experiments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Cancer phase I clinical trials: efficient dose escalation with overdose control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

A curve-free method for phase I clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Some practical improvements in the continual reassessment method for phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

A comparison of two phase I trial designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Continual reassessment method: a likelihood approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Pediatric drug labeling: improving the safety and efficacy of pediatric therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Minimum effective dose of midazolam for sedation of mechanically ventilated neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

An approach for dose finding of drugs in infants: sedation by midazolam studied using the continual reassessment method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Tocolytic effects of intravenous nitroglycerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Oxytocin requirements at elective cesarean delivery: a dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Assessment of intubating conditions in adults after induction with propofol and varying doses of remifentanil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Analysis of time trends in adaptive designs with application to a neurophysiology experiment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Bayesian decision procedures based on logistic regression models for dose-finding studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

Newborns and drug studies: The NICHD/FDA newborn drug development initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508098788

21 January 2018

Identifiers

DOI

10.1177/1740774508098788

1 reference

20 December 2017

1 reference

20 December 2017